Neuberger Berman Group LLC Has $131.18 Million Holdings in Pfizer Inc. (NYSE:PFE)

Neuberger Berman Group LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 64.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,945,893 shares of the biopharmaceutical company’s stock after selling 9,001,249 shares during the period. Neuberger Berman Group LLC’s holdings in Pfizer were worth $131,175,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently modified their holdings of the business. Retirement Wealth Solutions LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $26,000. Rialto Wealth Management LLC bought a new stake in Pfizer in the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC bought a new position in shares of Pfizer in the fourth quarter worth about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer during the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new position in Pfizer in the 4th quarter worth approximately $32,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 3.0 %

PFE stock opened at $22.50 on Thursday. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The business has a 50 day moving average price of $25.42 and a two-hundred day moving average price of $26.51. The company has a market cap of $127.61 billion, a price-to-earnings ratio of 15.96, a P/E/G ratio of 0.64 and a beta of 0.67. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group dropped their price target on Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Finally, Hsbc Global Res upgraded Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $31.07.

Insider Buying and Selling at Pfizer

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the company’s stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.06% of the stock is owned by corporate insiders.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.